Qx Therapeutics Inc., founded in 2017, is a Delaware corporation operating in Connecticut, US.

Qx Therapeutics Inc. is a drug research and development company aiming to provide innovative treatment toward unmet medical needs in the acute lung injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) disease area.

What We've Achieved

Stemmed from the revolutionary technology of MAP3K2/3 inhibition discovered by Dr. Dan Wu’s laboratory at Yale University, Qx Therapeutics is developing MAP3K2/3 inhibitors for the treatment of ALI and ARDS conditions with a unique mechanism of action. ALI and ARDA result from many diseases and factors. It is believed that an effective treatment of ALI and ARDS will have immerse impact on large population of patients.

What We are doing

We are aiming to submit an original IND in 2020 for our lead project QXT-101. The IND-opening clinical trial is planned to be a Phase II trial enrolling lung transplant patients for the treatment of Primary Graft Disfunction (PGD) as a form of ALI.